Positions

Selected Publications

Academic Article

Year Title Altmetric
2020 Protein kinase 2 (CK2) controls CD4+ T cell effector function in the pathogenesis of colitis 2020
2019 Novel biomanufacturing platform for large-scale and high-quality human T cells production 2019
2019 Deficiency of Socs3 leads to brain-targeted experimental autoimmune encephalomyelitis via enhanced neutrophil activation and ROS production 2019
2018 CK2 controls Th17 and regulatory T cell differentiation through inhibition of FoxO1 2018
2018 Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases 2018
2018 Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease 2018
2017 The Matrikine Acetylated Proline-Glycine-Proline Couples Vascular Inflammation and Acute Cardiac Rejection 2017
2017 Protein kinase CK2 controls the fate between Th17 cell and regulatory T cell differentiation 2017
2016 Erratum: SOCS3 deficiency promotes M1 macrophage polarization and inflammation (Journal of Immunology (2012) 189 (3439-3448)) 2016
2016 Inhibition of the JAK/STAT pathway protects against α-synuclein-induced neuroinflammation and dopaminergic neurodegeneration 2016
2016 Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma 2016
2016 Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury 2016
2015 SOCS3 deficiency in myeloid cells promotes tumor development: Involvement of STAT3 activation and myeloid-derived suppressor cells 2015
2015 Opportunities for translation from the bench: Therapeutic intervention of the JAK/STAT pathway in neuroinflammatory diseases 2015
2015 Preferential recruitment of neutrophils into the cerebellum and brainstem contributes to the atypical experimental autoimmune encephalomyelitis phenotype 2015
2014 Perk-dependent activation of JAK1 and STAT3 contributes to endoplasmic reticulum stress-induced inflammation 2014
2014 Therapeutic efficacy of suppressing the JAK/STAT pathway in multiple models of experimental autoimmune encephalomyelitis 2014
2014 Tlr4 regulates IFN-γ and IL-17 production by both thymic and induced Foxp3+Tregsduring intestinal inflammation 2014
2013 ERK differentially regulates Th17- and Treg-cell development and contributes to the pathogenesis of colitis 2013
2013 AMP-activated protein kinase restricts IFN-γ signaling 2013
2012 SOCS3 deficiency promotes M1 macrophage polarization and inflammation 2012
2012 Regulation of CCL20 expression in astrocytes by IL-6 and IL-17 2012
2012 Signal transducer and activator of transcription-3/suppressor of cytokine signaling-3 (STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation 2012
2012 ELISA methodology to quantify astrocyte production of cytokines/chemokines in vitro 2012
2011 ACK2-dependent mechanism for activation of the JAK-STAT signaling pathway 2011
2011 Th17 cells induce colitis and promote Th1 cell responses through IL-17 induction of innate IL-12 and IL-23 production 2011
2010 Generation of mucosal dendritic cells from bone marrow reveals a critical role of retinoic acid 2010
2010 Suppressor of cytokine signaling 3 inhibits antiviral IFN-β signaling to enhance HIV-1 replication in macrophages 2010
2010 IL-27 inhibits OSM-mediated TNF-α and iNOS gene expression in microglia 2010
2010 IL-17 enhancement of the IL-6 signaling cascade in astrocytes 2010
2010 Astrocyte-Restricted Ablation of Interleukin-17-Induced Act1-Mediated Signaling Ameliorates Autoimmune Encephalomyelitis 2010
2009 TGF-β promotes Th17 cell development through inhibition of SOCS3 2009
2008 Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes 2008
2008 Molecular basis of oncostatin M-induced SOCS-3 expression in astrocytes 2008
2008 The IFN-γ-induced transcriptional program of the CIITA gene is inhibited by statins 2008
2007 Molecular mechanism of lipopolysaccharide-induced SOCS-3 gene expression in macrophages and microglia 2007
2007 Simvastatin inhibits IFN-γ-induced CD40 gene expression by suppressing STAT-1α 2007
2007 Type I interferons as anti-inflammatory mediators. 2007
2006 IL-10 inhibits lipopolysaccharide-induced CD40 gene expression through induction of suppressor of cytokine signaling-3 2006
2006 IFN-β-induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microglia 2006
2006 IFN-beta-induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microglia. 2006
2005 LPS induces CD40 gene expression through the activation of NF-κB and STAT-1α in macrophages and microglia 2005
2004 Differential gene expression modulated by the cytoplasmic domain of FcγRIa (CD64) α-chain 2004
2004 Erratum: TRADD interacts with STAT1-α and influences interferon-γ signaling (Nature Immunology (2004) vol. 5 (199-207)) 2004
2004 TRADD interacts with STAT1-α and influences interferon-γ signaling 2004
2002 Diversity and duplicity: Human Fcγ receptors in host defense and autoimmunity 2002
2002 The CY domain of the FcγRIa α-chain (CD64) alters γ-chain tyrosine-based signaling and phagocytosis 2002
2001 Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-γ and IFN-β: Critical role of STAT-1α 2001
1999 The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells 1999
1998 Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-α and IFN-γ1 1998
1997 TGF-β Suppresses IFN-γ Induction of Class II MHC Gene Expression by Inhibiting Class II Transactivator Messenger RNA Expression 1997

Principal Investigator On

Investigator On

  • Innate and Adaptive Immunity in Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Innate and Adaptive Immunity in Parkinson Disease - Project 1: Role of Innate Immune Cells in Human Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Innate and Adaptive Immunity in Parkinson Disease - Project 2: Validating the JAK/STAT Pathway as a Novel Therapeutic Strategy in PD  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Therapeutic Intervention of the JAK/STAT Pathway for Neuroinflammation  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2013 - 2020
  • Private Grant  awarded by Pfizer Pharmaceuticals 2019 - 2020
  • Innate and Adaptive Immunity in Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2018
  • Innate and Adaptive Immunity in Parkinson Disease - Project 2  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2018
  • Innate and Adaptive Immunity in Parkinson Disease - Project 3: Role of Myeloid Cells in Human Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2018
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2017 - 2018
  • The Role of the JAK/STAT Pathway in Human Parkinson's Disease  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2017 - 2018
  • Targeting the JAK/STAT Pathway in the Treatment of Parkinson's Disease  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2015 - 2016
  • Targeting the JAK/STAT Pathway in the Treatment of Parkinson's Disease  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2012 - 2014
  • Therapeutic Intervention of the JAK/STAT Pathway for Treatment of Neuroinflammation  awarded by National Multiple Sclerosis Society 2013

    • Education And Training

  • Doctor of Philosophy in Cell Biology and Anatomy, University of Alabama at Birmingham 1999
  • Doctorate, 1986

    • Full Name

  • Hongwei Qin